Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Melanoma

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 7 articles:
HTML format



Single Articles


    September 2022
  1. LIVINGSTONE E, Zimmer L, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01654.
    PubMed     Abstract available


  2. SMITHY JW, Postow MA
    Adjuvant checkpoint blockade following complete local therapy for melanoma metastases.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01748.
    PubMed    


    August 2022
  3. HINDIE E
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed?
    Lancet. 2022;400:559.
    PubMed    


  4. LUKE JJ, Ibrahim N, Eggermont AM
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply.
    Lancet. 2022;400:559-560.
    PubMed    


    April 2022
  5. TCHERNEV G, Chokoeva AA
    Melanoma in a Chinese dragon tattoo.
    Lancet. 2022;399:e37.
    PubMed    


    March 2022
  6. LUKE JJ, Rutkowski P, Queirolo P, Del Vecchio M, et al
    Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
    Lancet. 2022 Mar 31. pii: S0140-6736(22)00562.
    PubMed     Abstract available


    September 2021
  7. CARLINO MS, Larkin J, Long GV
    Immune checkpoint inhibitors in melanoma.
    Lancet. 2021;398:1002-1014.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: